Rafael_Wiedenmeier
Roche (OTCQX: RHHBY) (OTCQX: RHHBF) on Thursday speak Its Vabysmo is as good as Bayer (OTCPK: BAYZF) (OTCPK: BAYRY) and Regeneron Pharmaceuticals’ (REGISTER) Eylea for the treatment of visual disturbances in two phase 3 studies.
The Swiss pharmaceutical giant has rated Vabysmo (faricimab) in two phase 3 trial, BALATON and COMINO, against Eylea (aflibercept) for the treatment of macular edema due to central and branch retinal vein occlusion (BRVO and CRVO). BALATON is being performed on 553 people with branch retinal vein occlusion, while COMINO is being performed in 729 people with central or central retinal vein occlusion.
Retinal vein occlusion (RVO) occurs when there is a blockage of a vein in the retina, which can lead to decreased vision.
Roche said both trials achieved their primary goal, showing that people with BRVO and CRVO-induced macular edema who received Vabysmo injections every four weeks, for up to 24 weeks, achieved visual acuity that was not inferior to that for those who received aflibercept injections every four weeks.
Vabysmo also showed rapid drying of retinal fluid from baseline to week 24, as measured by reduction in central subfield thickness, a secondary goal of the study.
The company added that Vabysmo is generally well tolerated and its safety profile is in line with previous trials.
Roche said detailed results will be presented to regulators globally and also presented at an upcoming medical meeting.
Vabysmo has approved in the US EU and some other countries for the treatment of age-related or ‘wet’ macular degeneration (nAMD) and diabetic macular edema (DME), the company notes.
